Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients

• Published in: Kidney international Vol. 67; no. 3; pp. 1171 - 1178
• Main Authors: Nakanishi, Shohei, Kazama, Junichiro James, Nii-Kono, Tomoko, Omori, Kentaro, Yamashita, Takeyoshi, Fukumoto, Seiji, Gejyo, Fumitake, Shigematsu, Takashi, Fukagawa, Masafumi
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.03.2005; Nature Publishing; Elsevier Limited
• Subjects: Adult; Aged; Biological and medical sciences; dialysis; Endocrinopathies; Female; FGF-23; Fibroblast Growth Factors - blood; Humans; hyperparathyroidism; Hyperparathyroidism, Secondary - blood; Hyperparathyroidism, Secondary - etiology; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Parathyroid Hormone - blood; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases); phosphate; PTH; Renal Dialysis - adverse effects; vitamin D; dialysis; phosphate; hyperparathyroidism; FGF-23; PTH; vitamin D; Endocrinopathy; Human; Phosphates; Fibroblast growth factor; Treatment resistance; Nephrology; Urology; Refractory; Parathormone; Vitamin D; Parathyroid hormone; Parathyroid diseases; Dialysis; Predictive factor; Serum factor; Hyperparathyroidism

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Secondary hyperparathyroidism is a common complication among long-term dialysis patients. The method of predicting future parathyroid function has not yet been established. Fibroblast gro...